Professional
Added to YB: 2025-01-30
Pitch date: 2024-12-31
ARGX [bullish]
argenx SE
+41.04%
current return
Author Info
No bio for this author
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 622.49
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Baron International Growth Fund Portfolio Holding: argenx SE
ARGX: Vyvgart FcRn inhibitor excelling in generalized myasthenia gravis & chronic inflammatory demyelinating polyneuropathy. Phase 2 success in myositis subsets, moving to Phase 3. Expect expanding efficacy across autoantibody-driven autoimmune conditions, driving market growth.
Read full article (1 min)